Journal of Clinical Oncology, Vol 15, 921-927, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

K Shirao, Y Shimada, H Kondo, D Saito, T Yamao, H Ono, T Yokoyama, H Fukuda, M Oka, Y Watanabe, A Ohtsu, N Boku, T Fujii, Y Oda, K Muro and S Yoshida
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

PURPOSE: A dose-escalation study of irinotecan hydrochloride (CPT-11) combined with fixed-dose cisplatin was conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and objective response rate in patients with advanced gastric cancer. PATIENTS AND METHODS: Twenty-four patients with or without prior chemotherapy were enrolled. All patients were assessable for toxicities and response. On day 1, CPT-11 was administered as a 90-minute intravenous (I.V.) infusion, which was followed 2 hours later by a 120-minute I.V. infusion of cisplatin 80 mg/m2. CPT-11 alone at the same dose was administered again on day 15. The treatment was repeated every 4 weeks until disease progression was observed. The initial dose of CPT-11 was 60 mg/m2, and was escalated in increments of 10 mg/m2 until severe or life-threatening toxicity was observed. RESULTS: The MTD of this combination was CPT-11 80 mg/m2. At this dose level, 16.7% of patients (two of 12) had leukopenia of less than 1,000/microL, 66.7% (eight of 12) had neutropenia of less than 500/microL, and 16.7% (two of 12) had severe diarrhea of grade 4 during the first course. The dose-limiting toxicity was neutropenia. Ten patients achieved a partial response (PR), and the overall response rate was 41.7% among 24 patients (95% confidence interval, 21.9% to 61.4%). CONCLUSION: The recommended dose and schedule is CPT-11 70 mg/m2 on days 1 and 15 and cisplatin 80 mg/m2 on day 1 every 4 weeks. This combination of CPT-11 and cisplatin, considered to be active against advanced gastric cancer with acceptable toxicity, should be further assessed in a phase II study.

This article has been cited by other articles:

				M. Dank, J. Zaluski, C. Barone, V. Valvere, S. Yalcin, C. Peschel, M. Wenczl, E. Goker, L. Cisar, K. Wang, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann. Onc., August 1, 2008; 19(8): 1450 - 1457. [Abstract] [Full Text] [PDF]

				S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]

				J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial Ann. Onc., August 1, 2004; 15(8): 1204 - 1209. [Abstract] [Full Text] [PDF]

				Y. Takahashi, J. Sakamoto, T. Takeuchi, M. Mai, T. Kubota, M. Kitajima, Y. Tanigawara, Y. Komatsu, T. Toge, and S. Saji A Randomized Phase II Clinical Trial of Tailored CPT-11 + S-1 vs S-1 in Patients with Advanced or Recurrent Gastric Carcinoma as the First Line Chemotherapy Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 342 - 345. [Abstract] [Full Text] [PDF]

				A. Ohtsu, Y. Shimada, K. Shirao, N. Boku, I. Hyodo, H. Saito, N. Yamamichi, Y. Miyata, N. Ikeda, S. Yamamoto, et al. Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205) J. Clin. Oncol., January 1, 2003; 21(1): 54 - 59. [Abstract] [Full Text] [PDF]

				W H Allum, S M Griffin, A Watson, and D Colin-Jones Guidelines for the management of oesophageal and gastric cancer Gut, June 1, 2002; 50 (2007): v1 - v23. [Full Text] [PDF]

				J. P. Stevenson, M. Redlinger, L. A.J. Kluijtmans, W. Sun, K. Algazy, B. Giantonio, D. G. Haller, C. Hardy, A. S. Whitehead, and P. J. O'Dwyer Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer J. Clin. Oncol., October 15, 2001; 19(20): 4081 - 4087. [Abstract] [Full Text] [PDF]

				M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]

				U. Vanhoefer, P. Rougier, H. Wilke, M. P. Ducreux, A. J. Lacave, E. Van Cutsem, M. Planker, J. G. D. Santos, P. Piedbois, B. Paillot, et al. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J. Clin. Oncol., July 14, 2000; 18(14): 2648 - 2657. [Abstract] [Full Text] [PDF]

				M. J. A. de Jonge, A. Sparreboom, A. S. T. Planting, M. E. L. van der Burg, M. M. de Boer-Dennert, J. t. Steeg, C. Jacques, and J. Verweij Phase I Study of 3-Week Schedule of Irinotecan Combined With Cisplatin in Patients With Advanced Solid Tumors J. Clin. Oncol., January 5, 2000; 18(1): 187 - 187. [Abstract] [Full Text] [PDF]

				M. J. A. de Jonge, J. Verweij, P. de Bruijn, E. Brouwer, R. H. J. Mathijssen, R. J. van Alphen, M. M. de Boer-Dennert, L. Vernillet, C. Jacques, and A. Sparreboom Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin J. Clin. Oncol., January 5, 2000; 18(1): 195 - 195. [Abstract] [Full Text] [PDF]

				D. H. Ilson, L. Saltz, P. Enzinger, Y. Huang, A. Kornblith, M. Gollub, E. O'Reilly, G. Schwartz, J. DeGroff, G. Gonzalez, et al. Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3270 - 3275. [Abstract] [Full Text] [PDF]

				R. F. DeVore, D. H. Johnson, J. Crawford, J. Garst, I. W. Dimery, J. Eckardt, S. G. Eckhardt, G. L. Elfring, L. J. Schaaf, C. K. Hanover, et al. Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2710 - 2710. [Abstract] [Full Text] [PDF]

				M. J. A. de Jonge, J. Verweij, A. S. T. Planting, M. E. L. v. d. Burg, G. Stoter, M. M. d. Boer-Dennert, P. d. Bruijn, E. Brouwer, L. Vernillet, and A. Sparreboom Drug-Administration Sequence Does Not Change Pharmacodynamics and Kinetics of Irinotecan and Cisplatin Clin. Cancer Res., August 1, 1999; 5(8): 2012 - 2017. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, Y. Shimada, K. Shirao, S. Seki, H. Saito, Y. Sakata, and I. Hyodo Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer J. Clin. Oncol., January 1, 1999; 17(1): 319 - 319. [Abstract] [Full Text] [PDF]

				J. A. Skirvin and V. Relias Review : Topoisomerase I inhibitors: 2. Irinotecan Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 103 - 116. [Abstract] [PDF]

				A. Bamias and N. Pavlidis Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today? Oncologist, June 1, 1998; 3(3): 171 - 177. [Abstract] [Full Text]

				L. B. Saltz Clinical Use of Irinotecan:Current Status and Future Considerations Oncologist, December 1, 1997; 2(6): 402 - 409. [Abstract] [Full Text] [PDF]